Navigation Links
Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
Date:8/19/2007

trial, could potentially support an accelerated registration strategy for tanespimycin in this life-threatening disease."

The TIME clinical program will utilize Kosan's improved, proprietary injectable suspension formulation of tanespimycin injectable suspension. The formulation is designed to provide important benefits, including improved patient safety, due to the elimination of Cremophor(R) and the associated need for steroid premedication to prevent hypersensitivity reactions. Tanespimycin injectable suspension also has a potentially enhanced intellectual property position and permits easier drug preparation and administration compared to the prior formulation.

The TIME-2 clinical trial is being conducted at clinical sites primarily in the US and in Europe and is anticipated to enroll approximately 130 patients. Key aspects of the TIME-2 trial are as follows.

-- The trial is designed to test three different doses of tanespimycin in

combination with the approved dose and schedule of bortezomib

(1.3 mg/m2). The tanespimycin dose groups are 50 mg/m2, 175 mg/m2 and

340 mg/m2. Tanespimycin will be administered twice weekly as a one-hour

intravenous infusion on a cycle of two weeks of treatment every three

weeks (the same schedule as bortezomib).

-- Patients eligible to participate in the TIME-2 trial must have been

treated with and progressed following at least three prior treatments

for multiple myeloma. Prior regimens must include bortezomib and

lenalidomide (Revlimid(R)).

-- The primary endpoint of the trial is the dose response based on

objective response rate after 4 cycles of treatment. Secondary

endpoints include a comparison of response rate between the dose

groups, progression-free survival, time to treatment failure and

overall survival. Objective response rate in multiple myeloma is

measured primarily by the pa
'/>"/>

SOURCE Kosan Biosciences Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
(Date:9/1/2014)... "Women struggle with weight gain typically associated to ... early as 15, if not earlier. Women therefore ... downs of hormone related weight gain. The battle ... to rage against the hidden and ever-present hormones which ... begin to face menopause and related changes, these hormonal ...
(Date:9/1/2014)... September 01, 2014 As well as ... Derek is currently pursuing counselor certification in Louisiana. ... through the CPI training program as well as the ... have grown both personally and professionally. I am ... am competently able to do so. As a ...
(Date:9/1/2014)... Parties involved in federally-filed Tylenol lawsuits ... status conference in September, where issues related to claims ... Eastern District of Pennsylvania, Bernstein Liebhard LLP reports. ... on the Court’s website, the meeting is scheduled to ... This is the latest of several Tylenol conferences that ...
(Date:9/1/2014)... 01, 2014 The Outlier Series announced ... exclusive interview content from one of the exceptional women ... Outliers: Women Game Changers . The title of the ... Game Changer Jenny McClendon . McClendon is currently a ... formerly the star of WeTV show, Raising Sextuplets. , ...
(Date:9/1/2014)... September 01, 2014 Psychogenic Non-epileptic Seizures ... a psychological disorder that can have devastating effects on ... like epileptic seizures however, they are not produced by ... triggers. It is estimated that the numbers of ... by multiple sclerosis. , Dr. Lorna Myers, ...
Breaking Medicine News(10 mins):Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 2Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 3Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2
... molecular mechanisms associated with the development and progression of ... The research, published by Cell Press in the January ... may lead to development of future strategies for treatment ... are derived from migratory neural crest cells that give ...
... January 5, 2008 Scientists from the Gladstone ... discovered that a certain type of collagen, collagen VI, ... widely thought to cause Alzheimer,s disease (AD). While the ... established, before this study it was unknown that collagen ...
... Oral-B Partner with Operation Smile to See the Difference, ... From January through March 2009, Crest and Oral-B are encouraging people ... own smile while also making a difference in children,s smiles worldwide. ... see the difference in their smile. People can also ...
... of infamous psychological obedience study in 1960s , , MONDAY, ... as willing to follow orders to hurt others as they ... , In a replication of one of the most famous ... give what they believed were increasingly painful electric shocks to ...
... Disability healthcare reform will be the subject of ... Disability (NCD) on Tuesday, January 13, 2009, from 3:00 ... held at the Chaparral Suites Resort, 5001 N. Scottsdale ... public. The forum will explore the relationship between health ...
... retinal cell gets infected with the common cytomegalovirus, contiguous ... may provide clues to better treatment of this potentially ... provide new insight into the larger issue of how ... a disease process such as diabetes, said Dr. Sally ...
Cached Medicine News:Health News:New insight into aggressive childhood cancer 2Health News:Collagen VI may help protect the brain against Alzheimer's disease 2Health News:Crest and Oral-B Challenge America to See The Difference in Their Smile and Make A Difference in Children's Smiles Around the World 2Health News:Crest and Oral-B Challenge America to See The Difference in Their Smile and Make A Difference in Children's Smiles Around the World 3Health News:Crest and Oral-B Challenge America to See The Difference in Their Smile and Make A Difference in Children's Smiles Around the World 4Health News:Researcher Finds Most Will Inflict Pain on Others If Prodded 2Health News:Researcher Finds Most Will Inflict Pain on Others If Prodded 3Health News:Disability Healthcare Policy Forum to Be Held in Scottsdale, Arizona 2Health News:Cell death from cytomegalovirus may bring new life to treatment of retinal disease 2
2.5mm...
... 12 bevel tip; silicone sleeve ... is opposite curve, Designed for ... Sleeve acts as stop & ... chance of trauma to the ...
Stab incision blades color coded for simple and accurate identification...
Formed 12.0mm from bend to tip; radius is 12.5 mm;, Curved sharp cutting edge requires less pressure to cut the capsule, reducing stress to zonules. 1.5mm long x .75 mm wide...
Medicine Products: